CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

William E. Fantegrossi

OPENALEX: A5045811374↗ORCID: 0000-0001-9964-1593↗

Affiliations

Organizations

University of Arkansas for Medical Sciencesauthorship · US

Public evidence

3 connected articles

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.2026 · Europe PMC Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135).2020 · Europe PMC Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity2011 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

William E. Fantegrossi - Medical Cannabis Research Engine